TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has released additional positive results from its Phase 1a dose-escalation trial of TTX-MC138, an investigational microRNA-10b inhibitor for advanced cancer. The study met its primary safety endpoint with no dose-limiting toxicities observed across 16 patients who received a total of 86 doses. These findings support the advancement of TTX-MC138 into Phase 2a clinical development.
The trial demonstrated durable disease stabilization in multiple patients. Among 14 evaluable patients, nine (64%) achieved stable disease lasting six months based on RECIST criteria. Notably, three participants remain on treatment after 14, 16 and 21 cycles. TransCode also reported pharmacokinetic data confirming drug bioavailability consistent with preclinical findings. A metastatic thyroid cancer patient experienced a significant decline in thyroglobulin levels and has maintained stable disease for 12 months.
Based on these results, the company has selected a recommended Phase 2a dose of 4.8 mg/kg. The data provide a rationale for continued clinical development in patients with limited treatment options. TTX-MC138 is designed to target metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis. TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers, with a portfolio of other first-in-class therapeutic candidates.
For more information, the full press release is available at https://ibn.fm/4WzoX. The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ.
